Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Aug 17:5:13110.
doi: 10.1038/srep13110.

Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer

Jiabei He  1 , Ying Hu  1 , Mingming Hu  1 , Baolan Li  1
Affiliations
Review

Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer

Jiabei He et al. Sci Rep. .

Abstract

Lung cancer is currently the leading cause of cancer-related death in worldwide, non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. Surgery, platinum-based chemotherapy, molecular targeted agents and radiotherapy are the main treatment of NSCLC. With the strategies of treatment constantly improving, the prognosis of NSCLC patients is not as good as before, new sort of treatments are needed to be exploited. Programmed death 1 (PD-1) and its ligand PD-L1 play a key role in tumor immune escape and the formation of tumor microenvironment, closely related with tumor generation and development. Blockading the PD-1/PD-L1 pathway could reverse the tumor microenvironment and enhance the endogenous antitumor immune responses. Utilizing the PD-1 and/or PD-L1 inhibitors has shown benefits in clinical trials of NSCLC. In this review, we discuss the basic principle of PD-1/PD-L1 pathway and its role in the tumorigenesis and development of NSCLC. The clinical development of PD-1/PD-L1 pathway inhibitors and the main problems in the present studies and the research direction in the future will also be discussed.

PubMed Disclaimer

References

    1. Hao J. & Chen W. Q. 2012 Chinese cancer registry annual report. 28–30 (Beijing Military medical Science Press, 2012).
    1. Zheng Y. W., Li R. M., Zhang X. W. & Ren X. B. Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome. Cancer Invest. 31, 197–205 (2013). - PubMed
    1. Sjöblom T. et al. The consensus coding sequences of human breast and colorectal cancers. J. Science. 314, 268–274 (2006). - PubMed
    1. Mosmann T. R. & Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 17, 138–46 (1996). - PubMed
    1. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. J. Nat Rev Cancer. 5, 263–274 (2005). - PubMed

MeSH terms